Fidaxomicin Versus Vancomycin for Clostridium dif fi cile Infection: Meta-analysis of Pivotal Randomized Controlled Trials for the Study 003/004 Teams
暂无分享,去创建一个
Mark A. Miller | T. Louie | T. Peto | D. Crook | B. Angus | N. Stoesser | S. Gorbach | B. Young | A. Walker | O. Cornely | R. Espósito | K. Weiss | Y. Kean
[1] D. Crook,et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.
[2] D. Altman,et al. The Problem of Subgroup Analyses: An Example from a Trial on Ruptured Intracranial Aneurysms , 2011, American Journal of Neuroradiology.
[3] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[4] T. Louie,et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. , 2010, Microbiology.
[5] Abdel Babiker,et al. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field , 2010, Clinical trials.
[6] Mark A. Miller,et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Stuart Johnson. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.
[8] D. Yokoe,et al. Clinical Risk Factors for Severe Clostridium difficile–associated Disease , 2009, Emerging infectious diseases.
[9] T. Louie,et al. OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection , 2008, Antimicrobial Agents and Chemotherapy.
[10] J. Karlowsky,et al. In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile , 2008, Antimicrobial Agents and Chemotherapy.
[11] C. Sabin,et al. Designing and interpreting HIV noninferiority trials in naive and experienced patients , 2008, AIDS.
[12] Jane W. Marsh,et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Melinda B Davis,et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] D. Gerding,et al. In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 , 2007, Antimicrobial Agents and Chemotherapy.
[15] Alan P. Johnson. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. , 2007, Current opinion in investigational drugs.
[16] J. Dipersio,et al. Severity of Clostridium difficile–Associated Disease (CDAD) in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD Severity Grading System , 2007, Infection Control & Hospital Epidemiology.
[17] Stuart Johnson,et al. An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.
[18] J. Pépin,et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] D. Musher,et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Carlene A. Muto,et al. A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.
[21] S. Finegold,et al. In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria , 2004, Antimicrobial Agents and Chemotherapy.
[22] P. Appelbaum,et al. Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species , 2004, Antimicrobial Agents and Chemotherapy.
[23] A. Rodloff,et al. In Vitro Activity of OPT-80 against Clostridium difficile , 2004, Antimicrobial Agents and Chemotherapy.
[24] A. Phillips,et al. Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection , 2004, AIDS.
[25] Lynne V McFarland,et al. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.
[26] W. Graninger,et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] D. Gerding,et al. PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.